All companies
Visit website
32 Biosciences
Operating32 Biociences, Inc.
Healthcare · Biotech · Founded 2023
Diversified life science company focused on gut microbiome medicine
Valuation cap ⓘ
$31.2M
As of Oct 2024 · from 32 Biosciences Crowd SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$508,598
Across 1 round since 2024
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its source$0
2022
$0
$3K
2023
$54K
−$1.7M
2024
$0
−$3.1M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$53,691
$0
Cost of goods sold
$0
$0
$0
$0
Gross margin
—
—
100%
—
Net income
$0
$3,111
-$1,742,797
-$3,091,429
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$0
$3,277
$1,183,699
$1,857,311
Accounts receivable
$0
$0
$0
$0
Total assets
$0
$3,227
$1,478,698
$2,091,486
Short-term debt
$0
$116
$14,917
$358,681
Long-term debt
$0
$0
$3,177,281
$5,378,215
Total liabilities
$0
$116
$3,192,198
$5,736,896
Other
Headcount
—
4
8
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$31.2M
Valuation cap
32 Biosciences Crowd SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $508.6K / $1.2MInvestors 236Valuation cap $31.2M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 2 of 2 annual reports (FY2024–FY2025)
236 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002020332
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.